NCT06502262View on ClinicalTrials.gov

A Comparative Study of Intrathecal Dexmedetomidine and Fentanyl As Additives to Bupivacaine in Pott's Fracture

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 15, 2024

Primary Completion Date

August 15, 2024

Study Completion Date

September 5, 2024

Conditions
Post Operative Pain
Interventions
DRUG

Bupivacaine Hydrochloride

patient will be given 3ml (15mg) of 0.5% hyperbaric bupivacaine + 0.5 ml of normal saline intrathecally.

DRUG

Fentanyl

patients will be given 3ml (15mg) of 0.5%hyperbaric bupivacaine +0.5ml (25 microgram) of fentanyl intrathecally

DRUG

Dexmedetomidine

patient will receive 3ml (15mg) of .05 hyperbaric bupivacaine 0.5ml(5 microgram) of diluted dexmedetomidine intrathecally

Trial Locations (1)

00202

Ain Shams University, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT06502262 - A Comparative Study of Intrathecal Dexmedetomidine and Fentanyl As Additives to Bupivacaine in Pott's Fracture | Biotech Hunter | Biotech Hunter